FCH
IMNM icon

Freestone Capital Holdings’s Immunome IMNM Stock Holding History

Freestone Capital Holdings’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Sell
61,514
-35
-0.1% -$779 0.04% 214
2025
Q4 		$1.32M Sell
61,549
-78
-0.1% -$1.37K 0.04% 215
2025
Q3 		$722K Buy
61,627
+28
+0% +$279 0.02% 280
2025
Q2 		$573K Sell
61,599
-82
-0.1% -$672 0.02% 276
2025
Q1 		$415K Buy
+61,681
New +$592K 0.02% 308

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Freestone Capital Holdings's IMNM Position: Q1 2026 in Review

Freestone Capital Holdings reduced its Immunome (IMNM) stake by 0.06% in Q1 2026, selling an estimated $779 and leaving 61,514 shares worth $1.35M. The position accounts for 0.04% of the portfolio, ranked #214.

Freestone Capital Holdings first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Freestone Capital Holdings held 61,514 shares of Immunome worth $1.35M as of Q1 2026.
  • Freestone Capital Holdings sold 35 Immunome shares in Q1 2026, an estimated $779.
  • Immunome made up 0.04% of Freestone Capital Holdings's portfolio in Q1 2026, its #214 holding.
  • Freestone Capital Holdings first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.